Drug recall · May 13, 2026
NAPROXEN ORAL SUSPENSION recall
Why: Chemical contamination; presence of lead and lithium above specification
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
NAPROXEN ORAL SUSPENSION, USP, 125 mg/5mL, Rx only, 16fl oz (473 mL) bottles, Distributed by: Acella Pharmaceuticals, LLC, Alpharetta, GA 30005, Made in Canada NDC 42192-619-16
- Lots / codes
Lot: 23F02, Expires: 05/2026; 25A37, Expires: 01/2028.
- Quantity
- 6,336 bottles
- Company
- Acella Pharmaceuticals, LLC, Alpharetta, GA
- Distribution
- Nationwide
- Initiated
- April 20, 2026 · Voluntary: Firm initiated
- Classified
- May 6, 2026
- Reported
- May 13, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Naproxen
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.